Search Results
Mar 31, 2026, 05:40 ET Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
group, the median time to deterioration (TTD) in global health status/quality of life (GHS/QoL) was not reached (vs 9.9 months for pembrolizumab), and the 12-month deterioration-free rate was 51% (vs 46%). The results published at ELCC2026, scores for GHS/QoL, physical function, and emotional function improved
More news about: Akeso, Inc.
Mar 31, 2026, 05:00 ET Even Under Financial Strain, Most Young People Still Find Reasons to Hope
financial strain are nearly two times more likely to rate their mental health as fair or poor compared with peers who feel financially comfortable (62% vs. 34%).Basic needs and well-being: Nearly two-thirds (63%) say difficulty affording basic necessities directly harms their mental health,
More news about: Hopelab
Mar 31, 2026, 03:56 ET SirPAD: Primary Results confirm the safety and efficacy of Sirolimus Coated Balloon in PAD
the sirolimus-coated balloon group vs. 15% in the uncoated balloon group at one year, corresponding to a median unbiased estimate of the risk difference of -4.9%. This difference was both noninferior and superior in favour of MagicTouch PTA (Concept Medical Inc.) vs. uncoated balloon. Furthermore, the
More news about: Concept Medical
Mar 31, 2026, 03:51 ET SirPAD: Primary Results confirm the safety and efficacy of Sirolimus Coated Balloon in PAD
the sirolimus-coated balloon group vs. 15% in the uncoated balloon group at one year, corresponding to a median unbiased estimate of the risk difference of -4.9%. This difference was both noninferior and superior in favour of MagicTouch PTA (Concept Medical Inc.) vs. uncoated balloon. Furthermore, the
More news about: Concept Medical
Mar 30, 2026, 20:00 ET Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
objective was to assess safety and tolerability (through Week 12 and Week 20). Prespecified exploratory efficacy objectives included the evaluation of OLN324 vs faricimab on visual acuity and various retinal anatomic parameters.About OLN324Building on the clinical success of intravitreal
More news about: Innovent Biologics
Mar 30, 2026, 19:25 ET Vale Base Metals Releases 2025 Exploration and 2026 Outlook Results; Copper Mineral Reserves and Mineral Resources Increase 6% to 53 million tonnes
inferred Mineral Resources have grown 26 per cent to a total of 7.3 Mt copper contained with additional Mineral Reserves of 0.8 Mt (growth 119 per cent vs 2024).
More news about: Vale Base Metals
Mar 30, 2026, 18:26 ET Vale Base Metals Releases 2025 Exploration and 2026 Outlook Results; Copper Mineral Reserves and Mineral Resources Increase 6% to 53 million tonnes
inferred Mineral Resources have grown 26 per cent to a total of 7.3 Mt copper contained with additional Mineral Reserves of 0.8 Mt (growth 119 per cent vs 2024).
More news about: Vale Base Metals
Mar 30, 2026, 17:36 ET LG Electronics celebra 30 anos de Brasil com arte, música e inovação
reorganizou suas operações em quatro divisões de negócios: Home Appliance Solution (HS), Media Entertainment Solution (MS), Vehicle Solution (VS) e Eco Solution (ES), redefinindo seus papéis e identidades para acelerar sua visão de futuro até 2030. Em 2024, as quatro divisões combinadas
More news about: LG Electronics Brasil
Mar 30, 2026, 17:28 ET LG lança QNED73 e convoca a torcida para viver o futebol em 2026
reorganizou suas operações em quatro divisões de negócios: Home Appliance Solution (HS), Media Entertainment Solution (MS), Vehicle Solution (VS) e Eco Solution (ES), redefinindo seus papéis e identidades para acelerar sua visão de futuro até 2030. Em 2024, as quatro divisões combinadas
More news about: LG Electronics Brasil
Mar 30, 2026, 17:27 ET LG Electronics Brasil renova patrocínio ao MIBR e reforça liderança no cenário de e-sports com a linha UltraGear
reorganizou suas operações em quatro divisões de negócios: Home Appliance Solution (HS), Media Entertainment Solution (MS), Vehicle Solution (VS) e Eco Solution (ES), redefinindo seus papéis e identidades para acelerar sua visão de futuro até 2030. Em 2024, as quatro divisões combinadas
More news about: LG Electronics Brasil
Mar 30, 2026, 17:24 ET LG Electronics mantém liderança global no mercado de TVs OLED e celebra 13 anos de excelência
reorganizou suas operações em quatro divisões de negócios: Home Appliance Solution (HS), Media Entertainment Solution (MS), Vehicle Solution (VS) e Eco Solution (ES), redefinindo seus papéis e identidades para acelerar sua visão de futuro até 2030. Em 2024, as quatro divisões combinadas
More news about: LG Electronics Brasil
Mar 30, 2026, 15:47 ET ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
seller Culper Research's report, "ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3.5% Real Growth in 2025 vs. +20% Reported."
More news about: Hagens Berman Sobol Shapiro LLP
Mar 30, 2026, 10:15 ET 1inch enables AI agents to access API suite, including swap execution, via MCP
directly into the developer workflow.Seamless integration & broad compatibility - One-line setup with support across 10+ tools (Cursor, VS Code, Claude, Codex, JetBrains, Gemini, etc.), enabling quick adoption in existing environments.As autonomous software becomes a core interface
More news about: 1inch
Mar 30, 2026, 08:00 ET Emboline Announces Positive Pivotal PROTECT H2H Trial Results for Emboliner® Presented as a Late-Breaking Clinical Trial at ACC 2026
statistical non-inferiority to control (4.5% vs. 5.0%; p for non-inferiority = 0.0004)Secondary safety/efficacy endpoint: (30-day stroke, VARC 2) was met, with Emboliner demonstrating statistical non-inferiority to control (2.0% vs. 2.1%; p for non-inferiority = 0.0001)Secondary
More news about: Emboline, Inc.
Mar 30, 2026, 08:00 ET Emboline Announces Positive Pivotal PROTECT H2H Trial Results for Emboliner® Presented as a Late-Breaking Clinical Trial at ACC 2026
statistical non-inferiority to control (4.5% vs. 5.0%; p for non-inferiority = 0.0004)Secondary safety/efficacy endpoint: (30-day stroke, VARC 2) was met, with Emboliner demonstrating statistical non-inferiority to control (2.0% vs. 2.1%; p for non-inferiority = 0.0001)Secondary
More news about: Emboline, Inc.
Mar 30, 2026, 08:00 ET Calliditas Therapeutics AB to Present Exploratory Biomarker and Post-Hoc NefIgArd Analyses at the World Congress of Nephrology
Presentations:Title: "Urine protein–creatinine ratio response at 12 months in patients with immunoglobulin A nephropathy receiving Nefecon vs placebo: Analysis of NefIgArd trial data"Date and time: March 28, 17:30 pm – 18:30 pm JSTPresenter: Richard Lafayette,
More news about: Calliditas Therapeutics
Mar 30, 2026, 07:43 ET CELEBRATING 25 YEARS AND BEYOND OF LIFE AFTER ORGAN TRANSPLANTATION AT THE NATIONAL UNIVERSITY CENTRE FOR ORGAN TRANSPLANTATION
survival for adult kidney transplant at 20 years is 76 per cent for living donor transplants (vs 66 per cent based on data from the Australia-New Zealand registry) and 67 per cent for deceased donor transplants (vs 50 per cent from the New Zealand registry). That so many at NUCOT have thrived for more than
More news about: National University Hospital (NUH)
Mar 30, 2026, 07:00 ET Monster Energy's Alexa Grasso Defeats Maycee Barber at UFC Fight Night in Seattle
UFC Fight Night 271: Adesanya Vs. Pyfer was contested in front of a live crowd of 17,854 spectators inside Climate Pledge Arena in Seattle. Featuring a total of six bouts on the Main
More news about: Monster Energy
Mar 28, 2026, 10:55 ET CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
non-inferiority compared to NOACs (5.7% vs. 4.8%; P<0.001).The study's secondary safety endpoint underscored the WATCHMAN FLX device is statistically non-inferior to NOACs at 36 months for procedural and non-procedural major bleeding (5.9% vs. 6.4%; P<0.001). Additionally, a secondary
More news about: Boston Scientific Corporation
Mar 28, 2026, 10:38 ET HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
superiority to anticoagulation alone (4.0% vs. 10.3%; P=0.005), representing a 61% reduction in primary endpoint events. Data from patients treated with the EKOS system also demonstrated a lower rate of cardiorespiratory decompensation or collapse (3.7% vs. 10.3%), in which inability of the heart to
More news about: Boston Scientific Corporation
Mar 27, 2026, 15:20 ET Monitores LG UltraGear OLED entregam imersão máxima para jogos de alta performance
reorganizou suas operações em quatro divisões de negócios: Home Appliance Solution (HS), Media Entertainment Solution (MS), Vehicle Solution (VS) e Eco Solution (ES), redefinindo seus papéis e identidades para acelerar sua visão de futuro até 2030. Em 2024, as quatro divisões combinadas
More news about: LG Electronics Brasil
Mar 27, 2026, 11:58 ET Guidepoint Library overtreft de grens van honderdduizend transcripten, breidt realtime toegang op schaal uit tot expertkennis
bedrijf, waarbij in de loop van de tijd een gelaagde context wordt opgebouwdWereldwijd perspectief: uitbreiding in de VS, EMEA en APAC in ontwikkelde en opkomende marktenPublieke en private markten: geïntegreerd inzicht in
More news about: Guidepoint
Mar 27, 2026, 11:41 ET OneBullEx Launches AI-Native Futures Infrastructure Platform, Integrating Quantitative Research Tools and Systematic Execution Architecture for the Crypto Derivatives Market
profits still accrue to institutional players with capital and co‑location privileges, and bots cannot rescue an inherently bad strategy.Manual vs algorithmic execution: a structural comparisonThe operational gap between manual and automated trading is widening across several dimensions.
More news about: OneBullEx
Mar 27, 2026, 11:27 ET OneBullEx Launches AI-Native Futures Infrastructure Platform, Integrating Quantitative Research Tools and Systematic Execution Architecture for the Crypto Derivatives Market
profits still accrue to institutional players with capital and co‑location privileges, and bots cannot rescue an inherently bad strategy.Manual vs algorithmic execution: a structural comparisonThe operational gap between manual and automated trading is widening across several dimensions.
More news about: OneBullEx
Mar 27, 2026, 10:44 ET Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. LEQSELVI is not approved for use in RA patients.MalignancyMalignancies have occurred in patients treated with LEQSELVI. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in
More news about: Sun Pharma